Papillary renal cell carcinomas are associated with chromosomal translocations involving the helix-loophelix leucine-zipper region of the TFE3 gene on the X chromosome. These translocations lead to the expression of TFE3 chimeras of PRCC, RCC17, NonO and PSF (PTB-associated splicing factor). In this study, we explored the role of PSF-TFE3 fusion protein in mediating cell transformation. Unlike wild-type TFE3 or PSF, which are nuclear proteins, PSF-TFE3 is not a nuclear protein and is targeted to the endosomal compartment. Although PSF-TFE3 has no effect on the nuclear localization of wild-type PSF, it sequesters wildtype TFE3 as well as p53 in the extranuclear compartment leading to functionally null p53 and TFE3 cells. In UOK-145 papillary renal carcinoma cells, which endogenously express PSF-TFE3, siRNA complementary to the PSF-TFE3 fusion junction leads to a reduction in PSF-TFE3 and redistribution of endogenous TFE3 and p53 from the cytoplasmic compartment to the nucleus. Our results indicate that PSF-TFE3 acts through a novel mechanism, and exports TFE3, p53 and possibly other factors from the nucleus to the cytoplasm for degradation leading to the transformed phenotype. Thus, PSF-TFE3 is a promising target for the treatment for a subset of renal cell carcinomas.
Introduction
Papillary renal cell carcinomas comprise about 10-20% of renal cell cancers. These tumors commonly exhibit a number of chromosomal abnormalities including tetrasomy of chromosome 7, trisomy of chromosomes 10, 12, 16 and 17, and/or loss of the Y chromosome (van den Berg et al., 1997) . Overexpression of genes located on these chromosomes has been suggested to contribute to the development of papillary renal cell carcinomas (Glukhova et al., 1998) . Another subset of these tumors show abnormalities in the chromosome Xp11 region that contains the gene for the transcription factor, TFE3. TFE3 is a member of class III helix-loop-helix (HLH) family and was originally identified as a protein binding to the mE3 region of the immunoglobulin heavy chain enhancer (Beckmann et al., 1990) . Although the various functions of TFE3 have not been completely defined, TFE3 has been reported to be important for stimulation of the plasminogen activator inhibitor 1 (PAI-1) gene promoter by TGF-b in conjunction with Smad3 and Smad4 (Hua et al., 1998) and for osteoclast development (Steingrimsson et al., 2002) .
TFE3 and related proteins of this HLH class (e.g. TFEB, TFEC, Mitf) are characterized by an additional leucine-zipper (LZ) domain (Massari and Murre, 2000) . TFE3 is a 566 amino-acid protein containing the bHLH DNA-binding domain (DBD), the LZ motif, an Nterminal potent acidic activation domain and a weaker C-terminal proline-rich activation region (Artandi et al., 1995) . The LZ domain is thought to be involved in homodimerization and heterodimerization with other family members such as TFEB (Fisher et al., 1991) , TFEC (Zhao et al., 1993) and Mitf (Mansky et al., 2002) and for binding to PU.1 of the ETS family (Tian et al., 1999) .
Several variants of papillary renal cell carcinomas involving translocation of the TFE3 gene have been identified by cytogenetic analysis including t(X;1)(p11.2;q21), t(X;1)(p11.2;p34), t(X;17)(p11.2;q25.3) and inv(X)(p11.2;q12). Cloning of these breakpoints have revealed the genes involved in these translocations as PRCC on 1q21 (Weterman et al., 1996) , PSF (PTBassociated splicing factor) on 1p34 (Clark et al., 1997) , RCC17 on 17q25.3 (Heimann et al., 2001) and NonO on Xq12 (Clark et al., 1997) , respectively. In cells containing these translocations, mRNAs expressing PRCC-TFE3, PSF-TFE3, RCC17-TFE3 and NonO-TFE3 have been identified but mRNA corresponding to the reciprocal translocation product is not consistently expressed.
Each of these translocations results in a predicted fusion protein containing the DBD and LZ region of TFE3 lacking its potent N-terminal activation domain. Thus, these fusion proteins might act by competing with wild-type TFE3 for TFE3-responsive genes (except for cells with the NonO-TFE3 X chromosome inversion which inactivates the TFE3 gene). Thus, a common feature of these different translocations is to either inactivate the TFE3 gene (NonO-TFE3) or to generate a fusion protein that could act by interfering the transcriptional effects of TFE3, perhaps on a gene(s) important for renal cell differentiation.
Our present study focuses on the mechanism leading to papillary renal cell carcinomas as a result of a translocation between the PSF and TFE3 genes located on chromosomes 1 and X, respectively (t(X;1)(p11.2;p34)) (Clark et al., 1997) . The PSF gene is reported to generate two spliced variants A and F at the mRNA level. PSF-A is a ubiquitously expressed 707 amino-acid nuclear protein that has an N-terminal region rich in proline and glutamine residues and two conserved RNA-binding domains (RBDs) in the central region of the protein (Patton et al., 1993) . PSF-A was initially reported to play a role as an essential splicing factor (Gozani et al., 1994) . However, our recent studies indicate that PSF-A interacts with nuclear hormone receptors, and acts as a transcriptional repressor through the recruitment of Sin3A and histone deacetylases (Mathur et al., 2001) . Other studies have also reported the involvement of PSF-A in repression (Sewer et al., 2002) as well as several other diverse functions (Chanas-Sacre et al., 1999; Akhmedov and Lopez, 2000; Rosenberger et al., 2002; Urban and Bodenburg, 2002) , suggesting that it might be a multifunctional protein. PSF-F mRNA is a second reported alternative spliced product of the PSF gene and encodes a protein of 669 amino acids, the first 662 being identical to PSF-A (Patton et al., 1993) . The PSF-TFE3 gene, found in some papillary renal cell carcinomas, utilizes this splice junction and the mRNA encodes the same 662 amino acids of PSF that are common to both PSF-A and PSF-F (Clark et al., 1997) .
In the course of studying whether PSF-TFE3 might repress TFE3-activated genes, we examined the cellular distribution of PSF-TFE3 as a green fluorescent protein (GFP) fusion in living cells. Unlike the ubiquitously expressed nuclear-localized PSF-A, PSF-TFE3 is not a nuclear protein and was identified as aggregate clusters in the extranuclear compartment of the transfected cells. Confocal microscopy studies indicate that PSF-TFE3 is targeted to the endosomal compartment and that it fully sequesters wild-type TFE3 from the nucleus to endosomes resulting in a functionally null TFE3 phenotype. Although PSF-TFE3 did not sequester a number of other nuclear proteins to the extranuclear compartment, we found that PSF-TFE3 also acted to sequester p53 outside the nucleus resulting in a p53 null phenotype. Extranuclear localization of endogenous TFE3, p53 and PSF-TFE3 in UOK-145 renal cancer cells, which express PSF-TFE3, was further confirmed by immunostaining. siRNA complementary to the PSF-TFE3 fusion junction leads to a reduction of PSF-TFE3 and to the nuclear localization of endogenous TFE3 and p53 in UOK-145 cells. Our studies indicate that PSF-TFE3 exists in an altered conformation that targets PSF-TFE3 to the endosomal compartment and that this altered conformation associates with and targets TFE3, p53, and possibly other factors, for degradation leading to the transformed phenotype.
Results
PSF-TFE3 is targeted to the extranuclear compartment of the cell PSF-A and TFE3 have been reported to be nuclear proteins (Weterman et al., 2000; Dye and Patton, 2001 ) and we confirmed this using GFP-PSF-A and GFP-TFE3 and fluorescent microscopy in COS-1 cells. GFP-PSF-A and GFP-TFE3 each localized in the cell nucleus, although they differ somewhat in their nuclear distribution pattern. GFP-PSF-A is found both in nuclear speckles and as a diffuse pattern in the nucleoplasm and is excluded from the nucleoli (Figure 1a ). In contrast, GFP-TFE3 exhibits a more diffuse pattern in the nucleus, does not localize to nucleoli, but is also found to some extent in the cytoplasm (Figure 1a) . In a few cells, GFP-TFE3 was only detected as a diffuse pattern in the cytoplasm as noted previously (Weterman et al., 2000) . In contrast with PSF-A and TFE3, PSF-TFE3 is only found as large aggregates in the extranuclear compartment ( Figure 1b ). When COS-1 cells were transfected to express different amounts of GFP-PSF-TFE3, the protein did not localize to the nucleus but was identified as aggregates just outside the nucleus. This pattern of distribution is unique to PSF-TFE3 and distinct from that of PSF-A and TFE3 expressed under the same conditions.
PSF-TFE3 targets TFE3 to the extranuclear compartment
Since PSF-TFE3 retains the dimerization domain of TFE3, we considered the possibility that PSF-TFE3 might bind TFE3 and sequester TFE3 from the nucleus to the extranuclear compartment. To explore this possibility, GFP-TFE3 was coexpressed with PSF-TFE3 in COS-1 cells. As shown in Figure 1a , GFP-TFE3 when expressed alone localizes to the cell nucleus and to some extent as a diffuse pattern in the cytoplasm. However, coexpression of GFP-TFE3 and PSF-TFE3 (Figure 2a ) leads to a similar perinuclear aggregate localization of GFP-TFE3 as found with GFP-PSF-TFE3 (Figure 1b ). This aggregate distribution of GFP-TFE3 when coexpressed with PSF-TFE3 is distinct from the diffuse cytoplasmic localization of GFP-TFE3 when expressed alone. In contrast with GFP-TFE3, coexpression of PSF-TFE3 with GFP-PSF-A did not affect the nuclear localization of PSF-A, the other fusion partner of PSF-TFE3 (Figure 2b ). We also coexpressed PSF-TFE3 with GFP-fusions of several other unrelated nuclear proteins (NRIF3, Sox9, NIF-1) (Li et al., 1999; Afonja et al., 2002; Mahajan et al., 2002) that were previously shown to localize to the nucleus of COS-1 cells. PSF-TFE3 did not alter the nuclear localization of any of these factors (data not shown).
TFE3 is targeted to the extranuclear compartment in papillary renal carcinoma cells that endogenously express PSF-TFE3
A cell line derived from a papillary renal cell carcinoma expressing PSF-TFE3 (UOK-145) was initially tested for expression of wild-type TFE3 and PSF-TFE3. Western blots performed on whole-cell lysates with antibody against TFE3 identified wild-type TFE3 (B65 kDa) and PSF-TFE3 (B130 kDa) (Figure 3 ). To assess whether endogenously expressed PSF-TFE3 in UOK-145 cells might sequester TFE3 in the extranuclear compartment as found in COS-1 cells, UOK-145 cells were transfected with varying amounts of plasmid vector expressing GFP-TFE3 (200 ng-1 mg). A representative study using 300 and 600 ng of GFP-TFE3 vector is shown in Figure 4a . In all studies, GFP-TFE3 was found as aggregates outside the nucleus with no evidence of nuclear localization. These results are similar to that found in COS-1 cells coexpressing PSF-TFE3 and GFP-TFE3. These findings are consistent with the notion that endogenous PSF-TFE3 in UOK-145 cells sequesters all the GFP-TFE3 to the extranuclear compartment as found in cotransfection experiments in COS-1 cells. In contrast with TFE3, endogenous PSF-TFE3 in UOK-145 cells had no effect on the distribution of PSF-A ( Figure 4b ). As found with COS-1 cells, the nuclear localization of GFP-fusions of Sox9, NRIF3, or NIF-1 also remains unaffected in UOK-145 cells (data not shown). These experiments in UOK-145 cells are consistent with our findings in COS-1 cells and provide additional evidence that PSF-TFE3, whether expressed exogenously or endogenously, can sequester TFE3 outside of the nucleus but has no effect on the nuclear localization of its other fusion component, PSF-A or several other nuclear proteins that were studied.
Immunocytochemistry studies were carried out with antibodies against TFE3 and PSF to study the distribution of endogenous TFE3, PSF, and PSF-TFE3 in UOK-145 cells. When cells are incubated with anti-TFE3 antibody followed by fluorescein-conjugated second antibody, green punctate aggregates were identified in the cytoplasm concentrated mainly in the perinuclear region. The nucleus appears to be completely devoid of any signal (Figure 4c , lower right-hand panel). Since TFE3 antibody recognizes both wild-type TFE3 and PSF-TFE3 in UOK-145 cells (Figure 3 ), both the proteins appear to be localized outside the nucleus. Anti-PSF antibody and fluorescein-conjugated second antibody were used to immunostain PSF in UOK-145 cells. A green fluorescent signal was found both in the nucleus and cytoplasm which would correspond to . This finding is consistent with our observation that GFP-PSF is nuclear localized in these cells and that the cytoplasmic aggregates would correspond to PSF-TFE3. These studies further confirm the cellular distribution of TFE3, PSF and PSF-TFE3 in UOK-145 cells expressing endogenous PSF-TFE3. In contrast, immunostaining of COS-1 cells with anti-PSF anibody detects only nuclearlocalized PSF (Figure 4c , upper left-hand panel). Anti-TFE3 antibody identifies TFE3 predominantly in the nucleus in COS-1 cells in addition to low levels of a somewhat diffuse cytoplasmic distribution (Figure 4c , lower left-hand panel). These observations are consistent with our transfections results in COS-1 cells indicating that GFP-PSF is a nuclear protein and that GFP-TFE3 is found in the nucleus and at low levels in the cytoplasm in COS-1 cells (Figure 1 ).
Extranuclear PSF-TFE3 and TFE3 localize to endosomal compartments in COS-1 and UOK-145 Cells
The precise localization of PSF-TFE3 and TFE3 in the extranuclear compartment was determined by confocal microscopy. GFP-PSF-TFE3 was expressed in COS-1 cells followed by internalization of the endosomalspecific marker transferrin conjugated to Texas-red for 20 min. Confocal serial sections of live cells were processed with image analysis software to identify overlapping (yellow) fluorescent signals. For this study, we used a Zeiss 510 laser scanning confocal microscope ( Â 100 PlanApo 1.4 NA objective). Remarkably, the majority of GFP-PSF-TFE3 localizes to the same compartment as transferrin as evident by the overlapping images shown in Figure 5a . In a similar experiment, when GFP-TFE3 was coexpressed with PSF-TFE3, almost all of the GFP-TFE3 was in endosomes ( Figure 5b ) as found for GFP-PSF-TFE3. When GFP-TFE3 is expressed alone in COS-1 cells, no GFP-TFE3 is found in the endosomal compartment ( Figure 5c ). Any cytoplasmic GFP-TFE3 in these cells is completely excluded from the endosomes, and the green fluorescence corresponding to GFP-TFE3 is distributed diffusely and uniformly throughout the cytoplasm. The endosomal vesicles filled with Texas-red-conjugated transferrin are completely devoid of GFP-TFE3 and no overlap was found in the localization of these proteins. Similar experiments were also carried out in UOK-145 cells that endogenously express PSF-TFE3. These cells were transfected with a vector expressing GFP-TFE3 followed by incubation with Texas-red-conjugated transferrin. Confocal microscopy indicated that in all the transfected cells, GFP-TFE3 colocalizes with transferrin ( Figure 6a ). Increasing the levels of expression of GFP-TFE3 resulted in an increase in the extent of green fluorescence accumulating in endosomes ( Figure 6b ).
To further confirm the localization of PSF-TFE3 and wild-type TFE3 in endosomal compartments, sucrose gradients were used to purify the endosomal fraction from UOK-145 cells preincubated with transferrin as an endosomal marker. The enriched endosomal fraction was analysed by SDS-PAGE followed by Western blotting with TFE3 antibody. The blot identified immunoreactive bands corresponding to the size predicted for PSF-TFE3 and for wild-type TFE3 ( Figure 6c , lane 1). The same fraction was also tested by Western Immunocytochemistry studies using anti-TFE3 antibody in UOK-145 cells reveal that endogenous TFE3 and PSF-TFE3 localize mainly in the extranuclear compartment (lower right-hand panel). The fluorescent signal detected by anti-PSF antibody in the nucleus and cytoplasm represents nuclear-localized PSF and extranuclear PSF-TFE3 (upper right-hand panel). Studies with COS-1 cells using anti-TFE3 antibody reveal that TFE3 is nuclear localized but is also found distributed at low levels diffusely in the cytoplasm (lower left-hand panel). Immunostaining these cells with anti-PSF antibody exhibits an exclusive nuclear pattern (upper left-hand panel)
PSF-TFE3 leads to a TFE3 and p53 null phenotype M Mathur et al blotting for transferrin ( Figure 6c , lane 2). An abundant immunoreactive band corresponding to transferrin (B80 kDa) was also detected in the same fraction, providing further evidence that PSF-TFE3 and wildtype TFE3 are targeted to endosomes in UOK-145 cells. We observed several immunoreactive species corresponding to TFE3 in the endosomal fraction, possibly resulting from an ongoing degradation process in these compartments. We also examined the distribution of these two proteins in other membrane fractions collected from the same sucrose gradient. No detectable amounts of either PSF-TFE3 or wild-type TFE3 was identified outside the endosomal fraction.
TFE3 does not activate gene expression in UOK-145 cells
The exclusive extranuclear localization of endogenous immunoreactive TFE3 and transfected GFP-TFE3 in UOK-145 cells suggests that endogenous TFE3 in these cells or exogenous expression of TFE3 might not lead to activation of TFE3-regulated genes. To test this possibility, these cells were transfected with a
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GFP-TFE3 a b c Figure 5 Confocal Microscopy identifies the endosomal compartment as the site of extranuclear sequestration of PSF-TFE3 and TFE3. COS-1 cells were transfected with vectors expressing (a) GFP-PSF-TFE3, (b) GFP-TFE3 and PSF-TFE3 or (c) GFP-TFE3. At 42 h after transfection, the cells were incubated with Texas-red-conjugated transferrin, an endosomal-specific marker, for 20 min at 371C followed by confocal microscopy of the live cells. Panel a shows two representative fields indicating that the majority of green fluorescence, corresponding to PSF-TFE3, resides in the same endosomal compartment(s) as transferrin (red) and thus appear yellow due to the overlap. The same is found for the sequestered GFP-TFE3 (b). Expression of GFP-TFE3 alone in COS-1 cells (c) shows two representative fields indicating a diffuse pattern of distribution both in the nucleus and the cytoplasm. However, GFP-TFE3 is excluded from the endosomal compartments as well as other vesicular structures PSF-TFE3 leads to a TFE3 and p53 null phenotype M Mathur et al chloramphenicol acetyltransferase (CAT) gene reporter ((mE3)4-TATA-CAT) containing four copies of a TFE3 response sequence (mE3). This TFE3 reporter gene showed no activity when transfected alone, or when cotransfected to express TFE3 indicating that TFE3 is not functionally active in UOK-145 cells (Figure 7a ). Longer incubation times for CAT assays using more protein and/or transfecting these cells with more plasmid DNA showed no activity of TFE3 reporter in these cells. To document that the CMV-based vector used to express TFE3 or GFP-TFE3 is functional in these cells, UOK-145 cells were also transfected with CMV-CAT, which resulted in high levels of CAT activity ( Figure 7a ). In contrast with UOK-145 cells, transfection of COS-1 cells with (mE3)4-TATA-CAT alone ( Figure 7b ) showed significant CAT activity, likely reflecting the endogenous expression of TFE3 in COS-1 cells (see Figure 3 ). Cotransfection with a vector expressing wild-type TFE3 resulted in further enhancement of activation (Figure 7b) . A reporter containing mutations that inactivate the TFE3 response sequence (m(mE3)4-TATA-CAT) showed no activity when transfected alone or with exogenous expression of TFE3 (Figure 7b ), indicating that the transcriptional activation observed with (mE3)4-TATA-CAT was TFE3 specific. We also examined the activity of a CAT reporter generated using the PAI-1 gene promoter (which has a TFE3-binding site) in UOK-145 cells alone or with exogenous expression of TFE3. No CAT activity was detected while the same PAI-1 gene reporter in COS-1 cells showed very high levels of activation (data not shown).
PSF-TFE3 targets p53 to the extranuclear compartment and functionally inactivates p53 activity
Our results indicate that PSF-TFE3 targets TFE3 to the extranuclear compartment in UOK-145 cells and generates a cell that is functionally null for TFE3 transcriptional activity. Our findings raise the possibility that inactivation of TFE3 by PSF-TFE3 might perturb the expression of a TFE3-regulated gene(s), which leads to cell transformation. This effect on TFE3 appeared to be relatively specific since the nuclear localization of In addition to TFE3, mutation and/or inactivation of the p53 tumor suppressor gene is a common finding in many renal cell cancers (Reiter et al., 1993; Oda et al., 1995; Hsueh et al., 2002) and in renal cell carcinoma cell lines (Angelo et al., 2002) . Although mutations of p53 disrupt its function, an alternative inactivation of wildtype p53 through its cytoplasmic sequestration has also been reported in a variety of human cell carcinomas (Moll et al., 1995) . No information, however, was available on the cellular distribution of p53 in UOK-145 cells, which prompted us to examine whether PSF-TFE3 might also affect the expression and/or its distribution in these cells. Western blotting with several monoclonal antibodies against p53 (122 and pAb240) that immunoreact with both mutant and wild-type p53, detected little or no p53 in UOK-145 cell extracts (data not shown), suggesting that either the p53 gene is expressed in very low amounts, or that p53 might be targeted to the extranuclear compartments where it is rapidly degraded. Although, p53 is not structurally related to PSF or TFE3, we considered the possibility that PSF-TFE3 might also target p53 to the cytoplasm leading to a p53 null phenotype.
Studies in COS-1 cells indicate that GFP-p53 localizes to the cell nucleus (Figure 8a ). However, coexpression of PSF-TFE3 and GFP-p53 leads to the extranuclear sequestration of GFP-p53 (Figure 8b ), similar to that found with PSF-TFE3 and GFP-TFE3 (Figure 2a ). This led us to investigate if p53 is localized in the cytoplasm in UOK-145 cells that express endogenous PSF-TFE3. Cells transfected with GFP-p53 were completely devoid of any GFP-p53 in the nucleus, However, similar aggregates were identified in the cytoplasm (Figure 8c ) as found for GFP-TFE3 in these cells. Further studies in UOK-145 cells, to test the transcriptional activity of p53, using a CAT reporter gene containing the mdm2 p53-response element (Qi et al., 1997) , showed no activity when transfected alone or with a vector expressing wild-type p53 (Figure 8d) . The same reporter, however, exhibits high activity in COS-1 (data not shown) and GH4C1 cells, which contain endogenous p53, and in HeLa cells when p53 is transiently expressed (Qi et al., 1997) . These studies, suggest that UOK-145 cells are functionally null for p53 transcriptional activity, supporting our finding that p53 is not a nuclear protein in these cells.
siRNA complementary to the PSF-TFE3 fusion junction leads to nuclear localization of endogenous TFE3 and p53 in UOK-145 cells
To assess whether endogenous p53 in UOK-145 cells also exhibits an extranuclear distribution, these cells were incubated with anti-p53 antibody followed by incubation with fluorescein-tagged second antibody. A punctate green fluorescent signal is detected in the cytoplasm in these cells with little or no p53 in the nucleus (Figure 9a ) consistent with the finding that these cells are null for p53 activity. In contrast, p53 is found exclusively in the nucleus in COS-1 cells (Figure 9b ). siRNA complementary to the PSF-TFE3 fusion junction was used to establish that endogenous PSF-TFE3 in UOK-145 cells is responsible for the cytoplasmic sequestration of TFE3 and p53 (Figure 10 ). Western blotting with antibody against TFE3 documented at least a 70% reduction in PSF-TFE3 (not shown). Control cells that were treated with transfection reagent but did not receive siRNA showed a nuclear and cytoplasmic distribution of immunoreactive PSF corresponding to PSF-A and PSF-TFE3, respectively, as well as extranuclear TFE3 and p53 (Figure 10a ). Cells transfected with the siRNA, however, showed only nuclear-localized PSF and a redistribution of TFE3 and p53 from the cytoplasmic compartment to the nucleus (Figure 10b ) documenting that the extranuclear localization of wild-type TFE3 and p53 in UOK-145 cells reflects sequestration by PSF-TFE3.
Discussion
Chromosomal translocations, involving the TFE3 gene on the X chromosome (Weterman et al., 1996; Clark et al., 1997; Heimann et al., 2001) , are common features in papillary renal cell carcinomas. These translocations result in the fusion of a number of genes (PRCC, RCC17, PSF and NonO) with the DBD and LZ dimerization region of TFE3. Although the TFE3 gene is common to these various translocations in kidney cancers, the mechanism(s) underlying the processes that UOK-145 cells were transfected with a TFE3-specific reporter ((mE3)4-TATA-CAT) either alone or with a CMV vector expressing TFE3. In all cases, this reporter is not activated by TFE3 in UOK-145 cells. CMV-CAT, which served as a control, shows high activity under the same assay conditions indicating that the CMV promoter is active in these cells. (b) When the same plasmids were used in COS-1 cells, the endogenous and exogenously expressed TFE3 activated the TFE3-reporter. This activity reflects an effect of TFE3 since no activity was found using a mutant TFE3-specific reporter (m(mE3)4-TATA-CAT) that does not bind TFE3
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In this study, we explored the mechanism(s) by which expression of PSF-TFE3 in a subset of papillary renal cell tumors might lead to and maintain the oncogenic phenotype. PSF-TFE3 contains the first 662 amino acids of PSF fused to the DBD and LZ dimerization region of TFE3 (Clark et al., 1997) . The potent N-terminal activation domain of TFE3 is not present in the chimera, while the PSF component of the chimera contains the repression domain of PSF-A, which interacts with Sin3A and histone deacetylases (Mathur et al., 2001) . Thus, we considered the possibility that PSF-TFE3 might act by targeting and repressing a TFE3 responsive gene important for renal cell differentiation. Such a mechanism would be analogous to that PSF-TFE3 leads to a TFE3 and p53 null phenotype M Mathur et al reported for PML-RARa and PLZF-RARa in acute promyelocytic leukemia (Lin et al., 1998) , and AML1-ETO in acute myeloid leukemia (Gelmetti et al., 1998) , where the fusion protein recruits histone deacetylases and represses genes important for myeloid differentiation, which bind RARa or ETO. However, our studies do not support such a mechanism. In contrast with PSF-A and TFE3, which are targeted to the cell nucleus, PSF-TFE3 is not a nuclear protein and is found exclusively in the form of perinuclear aggregates. Confocal microscopy studies in transfected COS-1 cells revealed that PSF-TFE3 is targeted to endosomal compartments; localization of GFP-PSF-TFE3 overlapped with that observed for transferrin, a known endosomal marker (Figure 5a ). The accumulation of PSF-TFE3 in endosomes per se, however, does not explain its role in cellular transformation. Thus, we explored whether PSF-TFE3 might target other factors to the endosomal compartment. Coexpression of PSF-TFE3 with GFP-TFE3 in COS-1 cells targeted GFP-TFE3 to the same endosomal compartment(s) as found for GFP-PSF-TFE3 (Figure 5b ). In contrast, PSF-TFE3 did not alter the nuclear localization of its other fusion partner, PSF-A as well as three other nuclear-localized transcription factors (Sox9, NRIF3 and NIF-1).
Studies with UOK-145 cells indicate that the level of expression of endogenous PSF-TFE3 is sufficient to target completely TFE3 to the endosomal compartment. Confocal and fluorescent microscopy studies indicate that when GFP-TFE3 is expressed in UOK-145 cells, the protein is only detected as perinuclear aggregates (Figure 6a ). With increasing levels of expression of GFP-TFE3, these extranuclear aggregates increase in size but no detectable TFE3 was identified in the nucleus in any of our experiments (Figure 6b ). This is consistent with our transfection studies with TFE3-reporter genes (Figure 7a ), which indicate that both endogenous and exogenously expressed TFE3 do not activate gene PSF-TFE3 leads to a TFE3 and p53 null phenotype M Mathur et al expression in these cells. That both endogenously expressed PSF-TFE3 and TFE3 localize to endosomes in UOK-145 cells is further supported by cell fractionation studies (Simon et al., 2000) . Various cellular fractions of UOK-145 cells were separated on sucrose gradients and were analysed by SDS-PAGE and Western blotting with antibody against TFE3. PSF-TFE3 and TFE3 were only identified in the purified endosomal fraction (Figure 6c ), which is consistent with our confocal microscopy results. Extranuclear localization of endogenous PSF-TFE3 and TFE3 in UOK-145 cells were further confirmed by immunocytochemistry studies (Figure 4c) . Previous studies have shown that PSF-A contains two nuclear-localization signals (Dye and Patton, 2001) . One is present at the extreme C-terminus of PSF-A (amino acids 701-707, PNKKPRF) and resembles a classical NLS (Dingwall and Laskey, 1991) . The second nuclearlocalization signal is located between amino acids 547-574 and resembles a bipartite or a tripartite NLS. Deletion of the last five C-terminal amino acids of PSF-A (KKPRF) contained within the C-terminal NLS resulted in a protein (PSF (1-702)) that accumulates outside the nucleus. Similarly PSF-F, the alternative spliced variant of PSF-A which also lacks the Cterminal NLS, appears to accumulate in the same manner in the perinuclear region (Dye and Patton, 2001 ). The exon-intron boundaries of the PSF-F variant are the same as the breakpoint of the PSF gene in PSF-TFE3 fusion protein (Clark et al., 1997) . Thus, both PSF-TFE3 and PSF-F contain the same first 662 amino acids of PSF-A, and lack the C-terminal NLS. Although the TFE3 DBD found in PSF-TFE3 contains a putative NLS, it does not appear sufficient to target PSF-TFE3 to the nucleus either alone or in conjunction with the second NLS of PSF.
The process by which PSF-TFE3 and TFE3 are targeted to endosomes is not well understood. PSF-TFE3 and wild-type TFE3 could possibly dimerize after their translation but fail to enter the nucleus due to the lack of the strong C-terminal NLS in PSF-TFE3. Instead the complex is targeted to endosomes, possibly due to the recognition of an altered conformation of the PSF moiety of PSF-TFE3 by endosomal surface receptors. We have not examined whether PSF-F also localizes to endosomes. However, the similar cell pattern of PSF-F and PSF-TFE3 aggregates suggest that it is the PSF moiety of PSF-TFE3 that targets the chimera to the endosomal compartment of the cell. Endosomes associated with GFP-TFE3 and GFP-PSF-TFE3 have the appearance of multivesicular bodies that are mostly perinuclear and concentrated near the microtubule organizing center. As endosomes mature they fuse with lysosomes, which would lead to the degradation of PSF-TFE3, TFE3, and any other associated factors. We have not tested for sequestration of other heterodimeric partners of TFE3 (e.g. TFEB, TFEC, and Mitf) which are also expressed in kidney (Steingrimsson et al., 2002) . However, the strong heterodimerization interactions of these proteins with TFE3 (Fisher et al., 1991; Zhao et al., 1993; Mansky et al., 2002) suggest that they could also be targeted to endosomes by PSF-TFE3 and their inactivation may play a role in mediating cell transformation.
The export of wild-type TFE3 from the nucleus to the cytoplasm by a mutant protein is a novel mechanism which leads to its inactivation and creats TFE3 null cells. The DBD and LZ region of TFE3 is the only common entity among all the fusion proteins (PSF-TFE3, NonO-TFE3, PRCC-TFE3, RCC17-TFE3 and ASPL-TFE3) associated with the development of papillary renal cell carcinoma. This suggests that the TFE3 DBD and LZ dimerization region in these fusion proteins plays an important role in mediating transformation and that they might also act through dimerization to sequester and inactivate TFE3 and related factors. Previous studies have shown that NonO-TFE3 and PRCC-TFE3 are nuclear proteins (Skalsky et al., 2001) , although their distribution within the nucleus is different from NonO, TFE3 or PRCC.
UOK-109 cells are a renal papillary carcinoma cell line that has been reported to express NonO-TFE3 but not wild-type NonO and TFE3. NonO-TFE3 does not appear to activate or repress TFE3 target genes when expressed in HepG2 cells (Skalsky et al., 2001) . In transfection studies using UOK-109 cells with TFE3-reporter genes alone or with vectors expressing wild-type TFE3, we found that these cells are also null for TFE3 transcriptional activity (Mathur and Samuels, unpublished observation) . This could possibly be due to sequestration of exogenously expressed TFE3 by NonO-TFE3 to a new location within the nucleus. Similarly, other heterodimeric partners of TFE3 could be sequestrated from their DNA-response sequences. Nevertheless, both NonO-TFE3 and PSF-TFE3 appear to lead to a TFE3 null phenotype. In contrast with the findings of PSF-TFE3 and NonO-TFE3, transfection studies in HepG2 cells with PRCC-TFE3 indicate that this fusion protein can stimulate the expression of the PAI-1 gene promoter (Skalsky et al., 2001) , a TFE3-responsive gene. Whether PRCC-TFE3 is similarly active on other TFE3 responsive genes in kidney cancers or whether it might function as a dominant-negative inhibitor of wild-type TFE3 or related HLH transcription factors in renal carcinoma cells is unknown.
Although PSF-TFE3 sequesters TFE3, it is unclear whether inactivation of TFE3 alone is sufficient to mediate transformation. For example, transformation may also require the inactivation of related HLH LZ proteins that are known to be expressed in the kidney (Steingrimsson et al., 2002) . Alternatively, PSF-TFE3 may also act to sequester proteins like p53 that are important for cell cycle regulation and tumor suppression. Remarkably, coexpression of PSF-TFE3 and GFP-p53 in COS-1 cells also sequestered GFP-p53 from the nucleus (Figure 8a ) to the extranuclear compartment (Figure 8b) and the distribution appears similar to that found for GFP-TFE3 when coexpressed with PSF-TFE3 (Figure 2a) . In addition, when GFP-p53 is expressed in UOK-145 cells that contain endogenous PSF-TFE3, all the GFP-p53 was found in the same perinuclear region as found with GFP-TFE3 in these cells (Figure 4a ).
Immunostaining of UOK-145 cells with anti-p53 antibody identified endogenous p53 as a punctate signal in the cytoplasm with very little or no p53 in the nucleus (Figure 9 ). The distribution pattern is similar to that identified for transfected GFP-p53 in UOK-145 cells (Figure 8 ). That p53 is inactivated in these cells, as a result of cytoplasmic sequestration, is also supported by transfection studies indicating that any endogenous or exogenously expressed p53 cannot activate a highly responsive p53-reporter gene (Figure 8d ), although the same reporter is active in COS-1 and other cell lines (Qi et al., 1997) . Additional evidence that the cytoplasmic sequestration of p53 (and TFE3) is due to PSF-TFE3 comes from an siRNA study indicating that a decrease in PSF-TFE3 expression results in a redistribution of p53 (and TFE3) from the cytoplasmic fraction to the nucleus.
Although it seems likely that PSF-TFE3 sequesters TFE3 through the TFE3 DBD LZ dimerization region common to both proteins, the mechanism by which PSF-TFE3 sequesters p53 is less clear. The N-terminal region of PSF in PSF-TFE3 contains a high glutamine and proline content. Thus, sequestration of p53 might occur through this domain of PSF in a similar fashion as reported for the sequestration of p53 by the expanded glutamine and proline residues of huntingtin, which is responsible for neuronal cell death in Huntington's Disease (Steffan et al., 2000) . Although the cellular distribution of the sequestered p53 differs (the nucleus for huntingtin and the cytoplasmic compartment for PSF-TFE3), in each case p53-mediated transcription is blocked by the interaction. Cytoplasmic sequestration of wild-type p53 has also been reported in undifferentiated neuroblastomas (Moll et al., 1995) and in some breast cancers and is thought to be one of the mechanisms to abrogate its tumor suppressing activity (Moll et al., 1992) . Although we have not ruled out that p53 in UOK-145 cells contains a mutation that could lead to its cytoplasmic localization and inactivation, our studies in COS-1 cells indicate that the expression of PSF-TFE3 leads to the cytoplasmic sequestration of an otherwise nuclear-localized GFP-p53 (Figure 8b) . Similarly, the extranuclear distribution of wild-type GFP-p53 in UOK-145 cells (Figure 8c ) that express endogenous PSF-TFE3 also suggests that PSF-TFE3 leads to its cytoplasmic sequestration.
Our results support the notion that the mechanism of transformation by PSF-TFE3 involves the inactivation of TFE3 (and/or related HLH proteins) as well as p53 and possibly other yet to be identified factors by cytoplasmic sequestration. Although it has been known for many years that transformation may involve the inactivation of certain transcription factors (e.g. p53 or Rb by SV40 large T-antigen) (Pipas and Levine, 2001) , our results indicate a new paradigm for transformation that involves the targeting and inactivation of transcription factors to the endosomal compartment by a fusion protein which exhibits unique properties and differs markedly from the wild-type proteins that contribute to its structure. By designing the appropriate therapeutic agents to inhibit the synthesis and/or the function of PSF-TFE3 oncoprotein in vivo, it should be possible to abrogate the oncogenic phenotype.
Materials and methods
Plasmids
Full-length TFE3, cloned into the GFP-C1 vector, was kindly provided by Graham Goodwin at the Haddow Laboratories, Sutton, Surrey, UK. GFP-PSF was constructed by inserting a PCR fragment of GFP in frame at the N-terminus of PSF cloned into a pCMX vector used previously in our studies (Mathur et al., 2001) . GFP-p53 was purchased from Clontech. GFP-NRIF3, GFP-Sox-9 and GFP-NIF-1 were previously described (Li et al., 1999; Afonja et al., 2002; Mahajan et al., 2002) .
PSF-TFE3 in pCMX was cloned as follows. The 3 0 end of PSF from nucleotide 2072 onwards (Accession # NM_005066) was replaced with the TFE3 sequence corresponding to the Cterminal TFE3 DBD and LZ region. pCMX-PSF-A was cleaved with BamHI (nt 1894) and XhoI (present at the 3 0 end of our clone) and replaced with a PCR fragment of PSF-A starting from the BamHI site at position 1894 to the site of fusion at nucleotide 2072. This PCR fragment was generated using a 3 0 primer that also contained a stretch of TFE3 sequence (Accession # X96717) from nt 1120 to the BsrGI site at nt 1148 and also has a XhoI site at the 3 0 end. The clone generated in this step was then digested with XhoI, blunt ended with Klenow enzyme and then digested with BsrGI. This was then used to insert the BsrGI (1148) and SmaI (3 0 end of TFE3) fragment of TFE3. This plasmid was sequenced at all the junctions to confirm the right reading frame of the protein.
To construct GFP-PSF-TFE3, the GFP-PSF vector was digested with XbaI to replace the part of PSF starting at nt 1106 to the end with XbaI-XbaI fragment from PSF-TFE3 in pCMX. All clones were verified by sequencing. The TFE3-specific reporter ((mE3)4-TATA-CAT), the mutant reporter (m(mE3)4-TATA-CAT) and TFE3 in a CMV-promoter-based expression vector (Carter et al., 1997) were kindly provided by Tom Kadesch at University of Pennsylvania School of Medicine, Philadelphia. The p53 CAT reporter MTV-59-CAT has been described previously (Qi et al., 1997 (Qi et al., , 1999 . It contains the 59 bp p53 response element of the human mdm2 gene and is highly responsive to p53 (Wu et al., 1993) .
Cell lines, cell culture, CAT assays
The UOK-145 cell line, derived from a papillary renal cell carcinoma with a translocation between the PSF and TFE3 genes on chromosomes 1 and X, was kindly provided by Colin S Cooper at the Haddow Laboratories, Sutton, Surrey, UK. The UOK-109 cell line was provided by WM Linehan at the National Cancer Institute, Bethesda, MD, USA. Cells were maintained in DMEM containing 10% fetal bovine serum and grown in 5% CO 2 . COS-1 cells were grown in 10% calf serum under the same conditions. Cell lines were transiently transfected using GenePORTER 2 transfection reagent from Gene Therapy Systems. For CAT assays, cells were plated at 60% confluency 1 day prior to transfection. Each well was transfected with 1 mg of reporter plasmid either with or without 1 mg of pCMV-TFE3. At 48 h after transfection, cells were washed twice in PBS and harvested by scraping into 20 mm Tris-HCl pH 7.8. The supernatant was collected by centrifugation and the protein was determined by using BioRad Reagent. CAT assays were performed with 10 mg protein.
Fluorescence microscopy
For fluorescence microscopy, cells were plated on coverslips in 24-well plates at 60% confluency 24 h prior to transfection. Localization of PSF, TFE3, p53 and other GFP-tagged transcription factors in COS-1 cells was assessed using 10 ng of expression vector DNA/well. GFP-PSF-TFE3-localization studies used 100-500 ng of plasmid depending on the size of the well. For competition studies, each 8-10 ng of vector expressing GFP-tagged protein was cotransfected with 400-600 ng of PSF-TFE3 expression vector or the corresponding molar amounts of control pCMX vector. To study the localization of GFP-tagged proteins in UOK-145 cells, the cells were transfected with varying amounts of expression vector (300-800 ng/well). The media was replaced 16 h later and 42 h after transfection the wells were washed four to five times with PBS and the cells were fixed with 3.7% formaldehyde at room temperature for 15 min. After washing the cells several times with PBS, the nuclei were stained with Hoechst dye (#33258) for 5 min and cells were washed again with water to remove excess stain. The coverslips were then mounted on a slide in Dako fluorescent mounting media and cells were observed using an Axioscope Fluorescence Microscope ( Â 40, PlanoApo 1.4 NA objective; ZEISS) equipped with the camera and digital imaging software. The digital images were viewed with Adobe Photoshop v5.0.
Immunostaining UOK-145 and COS-1 cells were grown on coverslips in 24-well plates. When the cells reach B60% confluency, they were fixed with 3.7% formaldehyde, permeabilized for 15 min in 3% BSA and 0.5% Triton X-100 in PBS, and then blocked with 3% BSA for 1 h. Cells were then incubated with polyclonal antibodies against TFE3 (Artandi et al., 1995) , PSF (Mathur et al., 2001) or monoclonal antibody against p53 (BP53.12 from Zymed), diluted in blocking buffer for 1 h, and then rinsed and incubated with fluorescein-conjugated second antibody in the dark (anti-mouse or anti-rabbit from Santa Cruz Biotechnology). After rinsing with PBS, the cells were incubated with Hoechst Stain for 5 min to visualize the nucleus and then rinsed again three to four times with PBS to remove excess stain. Coverslips were mounted in DAKO mounting media with the cell side down.
Inhibition of PSF-TFE3 expression with siRNA
For siRNA studies (Hannon, 2002; Paddison and Hannon, 2002) , a 21 bp siRNA complementary to the PSF-TFE3 fusion junction target sequence (5 0 -AA GUG ACA UGC UGC CUG UGU C-3 0 ) was synthesized by Dharmacon Research Inc. UOK-145 cells were plated in six-well plates 1 day prior to siRNA transfection. GeneSilencer siRNA transfection reagent (GeneTherapy Systems Inc.) was used to transfect UOK-145. The final concentration of siRNA in each well was 120 nm. Cells that received the same amount of transfection reagent without siRNA served as a control. Cells were harvested 72 h post-transfection with trypsin-EDTA and replated on glass coverslips in 24-well plates and incubated overnight. The next day the cells were fixed and immunostained with antibodies against PSF, p53 and TFE3.
Confocal microscopy
For confocal microscopy, cells were plated on glass bottom microwell dishes (35 mm petridish, 14 mm microwell) purchased from MatTek Corporation at 60% confluency 1 day prior to transfection. COS-1 cells were transfected with 200 ng of GFP-TFE3, with GFP-TFE3 and 2 mg of PSF-TFE3, or 2 mg of GFP-PSF-TFE3. Each 35 mm dish of UOK-145 cells was transfected with 2 or 4 mg of GFP-TFE3 plasmid DNA. Media was replaced after 16 h and cells were grown for another 24 h. Just prior to observing live cells with confocal microscopy, the cells were incubated with Texas-red-conjugated transferrin (100 mg/ml, Molecular Probes) for 20 min at 371C, and then washed with fresh media before imaging using a 510 laser scanning confocal microscope ( Â 100 PlanApo 1.4 NA objective; ZEISS). Digital images were viewed with Adobe Photoshop v5.0.
Preparation of endosomes from UOK-145 cells
Three 90% confluent 150 mm diameter plates of UOK-145 cells were used for preparation of endosomes by a modification of the method as described by Simon et al. (2000) . Cells were harvested with trypsin-EDTA and washed four times with Hanks buffered saline solution (HBSS). The suspended cells were then incubated with a solution of biotin-labeled transferrin and then washed with HBSS to remove excess transferrin. The crude homogenate was fractionated in a discontinuous sucrose gradient and the endosome fraction migrating at 0.9 m sucrose was collected and analysed for PSF-TFE3, TFE3 and transferrin by Western blotting.
Western blotting
To make whole-cell lysates, COS-1 and UOK-145 cells were incubated in lysis buffer (20 mm HEPES (pH 7.8), 0.42 m NaCl, 1.5 mm MgCl2, 0.2 mm EDTA, 0.5 mm DTT, 0.5 mm PMSF, 20% glycerol and 1% NP-40) and centrifuged for 10 min in cold. The supernatant was electrophoresed in 8.0% SDS-PAGE, transferred to nitrocellulose, followed by Western blotting with R4 polyclonal antibody against TFE3 (generously provided by Dr K Calame, College of Physicians and Surgeons, Columbia University, New York). To detect biotinlabeled transferrin in endosome fractions the blot was incubated with HRP-conjugated streptavidin. The blots were developed using the Pierce super signal chemiluminescence system.
